Andrew E. Sloan

TL;DR: Patient age is associated with not receiving effective therapies and hence worse prognosis in clinical neurooncology, and survival variation correlated with treatment combinations.

TL;DR: A novel mechanism mediating tumor hypoxic responses linking microenvironmental regulation of epigenetic-modifying proteins to cellular heterogeneity is uncovered and provides rationale for the design of more sophisticated clinical approaches targeting epigenetic regulation.

TL;DR: In this paper, the authors suggest that GTR or STR should be performed instead of biopsy alone when safe and feasible so as to decrease the frequency of tumor progression recognizing that the rate of progression after GTR is fairly high.

TL;DR: Age-adjusted incidence rates per 100,000 population for pituitary tumors with ICD-O-3 (International Classification of Diseases for Oncology, Third Edition) histology codes 8040, 8140, 8146, 8246, 8260, 8270, 8271, 8281, 8290, 8300, 8310, 8323, 9492 were calculated overall and by patient sex, race, Hispanic ethnicity, and age at diagnosis.

TL;DR: Tumors in the brain, prostate, thorax, and bone can be clearly visualized with [18F]FMAU and in the upper abdomen, visualization is limited by the physiological uptake by the liver and kidneys.